Abstract

Background and aim. The combination of Sofosbuvir (SOF) and Ledipasvir (LDV) has been lead to considerable enhancement of treatment of hepatitis C virus (HCV) genotype 1 infection. A meta-analysis of the currently available studies was undertaken with the aim to evaluate the antiviral efficacy of SOF/LDV therapy for 12 or 24 weeks with or without Ribavirin (RBV) in patients with HCV genotype 1 infection. Material and methods. In this meta-analysis, we searched databases including PubMed, Scopus, Science Direct and Web of Science using appropriate keywords. All papers which evaluated the efficacy of combination therapy of SOF/LDV with or without RBV for 12 or 24 weeks among patients with HCV genotype 1 infection were included. Results. The 20 published articles were assessed for eligibility and finally 10 articles pooling 2248 participants were included in this meta-analysis. Pooled SVR12 for four SOF/LDV regimens were 95 (95CI = 93-97) for 12 weeks of treatment with SOF/LDV, 97 (95CI = 95-98) for 24 weeks of treatment with SOF/LDV, 96 (95CI = 94-97) for 12 weeks for treatment with SOF/LDV/RBV and 98 (95CI = 97-99) for 24 weeks of treatment with SOF/LDV for 12 weeks cirrhosis had a significant effect on the SVR12(OR = 0.21, 95CI = 0.2-0.5). Conclusion. The Interferon-free regimen of SOF/LDV for 12 or 24 weeks with or without RBV is highly effective for treatment of patients with HCV genotype 1 infection.